Creative Medical Technology Holdings Inc (CELZ)

Jul 17, 2025, 9:15 AM EDT - 22 days ago

Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells

Jul 11, 2025, 8:01 AM EDT - 4 weeks ago

Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelz™ for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling

Mar 20, 2025, 7:50 AM EDT - 5 months ago

Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain

Mar 6, 2025, 8:10 AM EST - 5 months ago

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds

Feb 14, 2025, 7:00 AM EST - 6 months ago

Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™

Feb 11, 2025, 9:25 AM EST - 6 months ago

Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program

Feb 5, 2025, 8:25 AM EST - 6 months ago

Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development

Jan 30, 2025, 9:25 AM EST - 6 months ago

Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain

Nov 25, 2024, 9:03 AM EST - 9 months ago

Top 3 Real Estate Stocks That May Explode In Q4

OPI WHLR

Nov 13, 2024, 9:00 AM EST - 9 months ago

Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment

Jul 24, 2024, 9:00 AM EDT - 1 year ago

Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program

Jul 10, 2024, 8:30 AM EDT - 1 year ago

Creative Medical Technology Holdings Provides Corporate Update

Jun 24, 2024, 8:30 AM EDT - 1 year ago

Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin

Mar 7, 2024, 9:15 AM EST - 1 year ago

Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access

Mar 6, 2024, 7:00 AM EST - 1 year ago

Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy

Dec 20, 2023, 9:35 AM EST - 1 year ago

Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain

Oct 10, 2023, 8:00 AM EDT - 1 year ago

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain

Aug 24, 2023, 10:45 AM EDT - 2 years ago

What Is Allogeneic Cell Therapy, And What's Driving This Market's 25%+ Annual Global Growth?

Jul 14, 2023, 9:00 AM EDT - 2 years ago

The Immunotherapy Market is Expected to Surpass $351.56 Billion by 2030 - Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) is Contributing to this Growth

Jul 13, 2023, 9:00 AM EDT - 2 years ago

Creative Medical Technology Reports Advancements In Regenerative Medicine And Improvements In Financial Position In Corporate Update

Jun 28, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements

Jun 12, 2023, 8:01 AM EDT - 2 years ago

Creative Medical Technology Announces $2 Million Share Repurchase Program

Jun 9, 2023, 12:30 PM EDT - 2 years ago

Creative Medical Technology Holdings Announces Reverse Stock Split

May 31, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz® Immunotherapy Platform

May 22, 2023, 8:30 AM EDT - 2 years ago

Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development

May 18, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line

Apr 12, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Announces Positive Top-Line Results for Type 2 Diabetes Study

Apr 4, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business Update

Mar 23, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA Using the ImmCelz® Platform for the Treatment of Brittle Type 1 Diabetes

Mar 21, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Announces Key Milestones Regarding ImmCelz® Platform Development

Mar 7, 2023, 8:00 AM EST - 2 years ago

Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201

Feb 14, 2023, 8:00 AM EST - 2 years ago

Three Year Follow-Up Results Confirm Efficacy of StemSpine® Procedure for Treating Chronic Lower Back Pain, with No Serious Adverse Effects

Feb 8, 2023, 8:00 AM EST - 2 years ago

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes

Nov 3, 2022, 7:30 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem™, a Novel Cell Therapy for the Treatment of Type 1 Diabetes

Oct 20, 2022, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Develops AlloStem™ Clinical Cell Line

Sep 26, 2022, 8:00 AM EDT - 3 years ago

Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study

Jul 28, 2022, 7:30 AM EDT - 3 years ago

Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study

Jun 15, 2022, 8:30 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. for Development of a Next Generation iPSC Pipeline for its ImmCelz® Immunotherapy Platform

Apr 29, 2022, 8:40 AM EDT - 3 years ago

Creative Medical Technology Announces $17 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 20, 2022, 8:30 AM EDT - 3 years ago

Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® Product

Apr 12, 2022, 8:30 AM EDT - 3 years ago

Creative Medical Technology to Showcase CaverStem® at American Urological Association Annual Meeting - Largest and Most Prominent Gathering of Urologists in the World

Mar 23, 2022, 10:15 AM EDT - 3 years ago

Why Creative Medical Technology Shares Are Soaring

Mar 23, 2022, 10:15 AM EDT - 3 years ago

Creative Medical Shares Soar On Positive Data from StemSpine Pilot Study

Mar 23, 2022, 8:30 AM EDT - 3 years ago

Creative Medical Technology Announces Positive Top-Line Results for StemSpine® Pilot Study

Mar 8, 2022, 8:30 AM EST - 3 years ago

Creative Medical Technology to Participate in the 34th Annual Roth Conference

Mar 2, 2022, 8:30 AM EST - 3 years ago

Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer

Dec 3, 2021, 4:00 AM EST - 4 years ago

Creative Medical Technology Holdings, Inc. Prices $16 Million Public Offering and Uplisting to the Nasdaq Capital Market

Nov 9, 2021, 4:45 PM EST - 4 years ago

Creative Medical Technology Holdings Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to The Nasdaq Capital Market